

References

- Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M and Hardy M *et al.* Randomized trial of tacrolimus plus mycophenolatemofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolatemofetil after cadaveric kidney transplantation: results at 2 years, *Transplantation* 72 (2) (2001); 245: 250.
- Aiello FB, Calabrese F, Rigotti P *et al.* Acute rejection and graft survival in renal transplanted patients with viral diseases, *Mod Pathol* (2004); 17: 189.
- Akbari, Hussain N and Karpinski J *et al.* Chronic kidney disease managment: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease, *Nephron ClinPract*107 (2007); 7.
- Allen and Chapman JR, *A Manual of Renal Transplantation*, Edward Arnold, London 1994; 127.
- Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS, Risk factors for chronic rejection in renal allograft recipients.*Transplantation.* (1993); 55(4): 752: 6.
- Amend WJ, Vincenti *et al.* The first three postansplant months. In: *Handbook of Kidney Transplantation*, 4th ed, Danovitch GM. (Ed), Lippincott Williams &Wilkins, Philadelphia, PA (2005).
- Bethesda MD, Richmond VA Annual report of the U.S. scientific registry of transplant recipients and the organ procurement and transplantation network: transplant data: 1990–1999. Public Health Services, Bureau of Health Resources Department, Division of Organ Transplantation, UNOS, (2000).

- Aragao E, Moura LA and Pacheco-Silva A. Monitoring anti-HLA class I IgG antibodies in renal transplant recipients, *Transplant Proc* 36 (2004); 836.
- Artz MA, Boots JM, Ligtenberg G, Roodnat, Christiaans JI MH and Vos PF *et al.*, Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile, *Am J Transplant* 4 (2004): 937–945.
- Arvizu-Hernández M, Morales-Buenrostro LE, Vilatoba-Chapa M, Mancilla-Urrea E, Uribe-Uribe N, Avila-Casado MC, Leo C, Arvizu A, Gonzalez JL, Torres J, Gabilondo B, Correa-Rotter R, Alberú J. Time of Occurrence of Kidney Acute Antibody-Mediated Allograft Rejection/Acute Cellular Rejection and Cell Senescence: Implications for Function Outcome, *Transplantation Proceedings*, Volume 42, Issue 7, (2010); 2486: 2492.
- Augustine JJ, Bodziak KA and Hricik DE. Use of sirolimus in solid organ transplantation, *Drugs* 67 (3) (2007); 369: 391.
- Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD and Becker BN *et al.* Outcomes at three years of a prospective pilot study of CAMPATH-1H and sirolimus immunosuppression for renal transplantation, *Transplant Int* 19 (11) (2006); 885: 892.
- Basadonna GP, Matas AJ and Gillingham KJ *et al.* Early versus late acute renal allograft rejection: Impact on chronic rejection. *Transplantation* 1993; 55: 993.
- Basu A, Ramkumar M and Tan HP *et al.* Reversal of acute cellular rejection after renal transplantation with Campath-1H. *Transplant Proc* (2005); 37: 923.
- Becker YT, Becker BN, Pirsch JD and Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. *Am J Transplant* (2004); 4: 996.

- Bennett W. Immunosuppression with mycophenolic acid: one size does not fit all. *J Am Soc Nephrol* (2003); 14: 2414: 2418.
- Böhmig GA, Regele H and Exner M et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. *J Am Soc Nephrol* (2001); 12: 2482.
- Briganti E, Russ G, McNeil J, Atkins R, Chadban S. Risk of renal allograft loss from recurrent glomerulonephritis. *N Engl J Med* (2002); 347: 103–109.
- Briggs D, Dudley C and Pattison J et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. *Transplantation*(2003); 75: 2058.
- Broeders N, Wissing KM and Crusiaux A et al. Mycophenolatemofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. *J Am Soc Nephrol* (1998); 9: 1521.
- Brown KL, El-Amm JM, Doshi MD, Singh A, Katherina Morawski RN, Cincotta E, Siddiqui F, Losanoff JE and West MS. Intermediate-terms outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipient, *The American Journal of Surgery* Volume 195, Issue 3, (2008); 298: 303.
- Burke JF, Pirsch JD, Ramos EL, Salomon DR, Stablein DM and Van Buren DH. et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients, *N Engl J Med* 331 (1994); 358: 363.
- Butler JA, Peveler RC, Roderick P, Smith PW. Horne R. and Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. *Nephrol Dial Transplant*. (2004); 19(12): 3144-9.

Calne R, Friend P, Moffatt S, Bradley A, Hale G and Firth J *et al.* Proper tolerance, perioperative CAMPATH 1H, and low-dose cyclosporin monotherapy in renal allograft recipients, *Lancet* 351 (9117) (1998); 1701: 1702.

Canadian Organ Replacement Register: Treatment of End-Stage Organ Failure in Canada 1995 to 2004, Ottawa, Ontario, Canada, Canadian Institute for Health Information, (2006).

Cantarovich D, Renou M, Meghribeto A, Giral-Classe M, Hourmant M and Dantal J *et al.* Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events, *Transplantation* 79 (1) (2005); 72: 78D.

Carpenter CB. Immunosuppression in organ transplantation. *N Engl J Med* (1990); 322: 1224.

Castillo-Lugo JA and Vergne-Marini P. Hypertension in Kidney Transplantation Seminars in Nephrology Volume 25, Issue 4, (2005); 252: 260.

Cecka JM And Terasaki PI. Early rejection episodes. In: *Clinical Transplants*, Terasaki PI. (ed), UCLA Tissue Typing Laboratory, Los Angeles, (1989); 425: 434.

Cecka JM, Cicciarella J, Mickey MR and Terasaki PI. Blood transfusions and HLA matching in either/or situation in cadaveric renal transplantation. *Transplantation* 45 (1988); 81.

Cecka JM. The UNOS transplant registry. In Cecka JM., Terasaki PI., eds. *Clinical Transplants* (2001). Los Angeles: UCLA, (2002); 1:18.

Chakkera HA, Chertow GM and O'Hare AM *et al.* Regional variation in kidney transplant outcomes; trends over time, *Clinical J Am Soc.Nephrol.* 4 (2009); 152.

- Charney DA, Nadasdy T, Lo AW And Racusen LC. Plasma cell-rich acute renal allograft rejection. *Transplantation* (1999); 68:791.
- Chkhotua AB, Klein T, Shabtai E, Yussim A, Bar N, Shaharabani E, Lustig S and Mor E. kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocolsurology, Volume 62, Issue 6,(2003);1002:1006.
- Christiaans MH, van Hooff JP. Plasmapheresis and RATG-induced serum sickness. *Transplantation* (2006); 81:296.
- Churchill DN, Torrance GW and Taylor DW *et al.*, Measurement of quality of life in end-stage renal disease: a time tradeoff approach, *Clin Invest Med* **10** (1987); 14.
- Ciancio G, Burke GW, Gaynor JJ, Ruiz P, Roth D and Kupin W *et al.*, A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis, *Transplantation***81** (2006);845:852.
- Clatworthy MR, Friend PJ and Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. *Transplantation* (2009); 87:1092.
- Cole EH, Johnston O, Rose CL and Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. *Clin J Am Soc Nephrol.* (2008); 3(3): 814-21.
- Colvin RB., Cohen AH. and Saiontz C., et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. *J Am Soc Nephrol* (1997); 8: 1930.

Cosio FG, Alamir A and Yim S. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. *Kidney Int* (1998); 53(3): 767-772.

Cosio FG, Pelletier RP and Falkenhain ME et al. Impact of acute rejection and early allograft function on renal allograft survival. *Transplantation* (1997); 63: 1611–15.

Csapo Z., Benavides-Viveros C., Podder H. et al. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. *Transplant Proc* (2005); 37:2032.

Danovitch GM And Cecka JM. Allocation of deceased donor kidneys: past, present, and future. *Am J Kidney Dis* (2003); 42: 882–90.

De Fijter JW, Mallat MJ And Doxiadis II, Ringers J, Rosendaal FR, Claas FH. and Paul LC., Increased immunogenicity and cause of graft loss of older donor kidneys. *J Am Soc Nephrol* (2001); 12 (7): 1538-1546.

Delmonico F. Council of the Transplantation Society: A report of the Amsterdam Forum on the Care of the Live Kidney Donor: data and medical guidelines. *Transplantation* (2005); 79(6):2-53.

Delmonico F. Exchanging kidneys. Advances in living-kidney transplantation. *N Engl J Med* (2004); 350: 1812–14.

Descamps-Latscha B, Herbelin A and Nguyen AT et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis: Relationships with activation markers of T cells, B cells, and monocytes. *J Immunol* **154** (1995): 882.

Desvaux D, Le Gouvello S. and Pastural M. et al., Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high

gamma-interferon expression and poor clinical outcome. *Nephrol Dial Transplant* (2004); 19: 933.

Desvaux D, Schwarzing M and Pastural M et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. *Transplantation*(2004); 78:647.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B and Gurkan A.*et al.*, ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation, *N Engl J Med***357** (25) (2007); 2562: 2575.

El-Agroudy AE, Donia AF and Bakr MA, Preemptive living-donor kidney transplantation: Clinical course and outcome. *Transplantation* (2004); 77(9): 1366-1370.

Emiroğlu **R**, Karakayali **F**, Haberal **C**, Ozcelik **U**, Colak **T** **and** Haberal **M**. Role of Donor Age and Acute Rejection Episodes on Long-Term Graft Survival in Cadaveric Kidney Transplantations. *Transplantation Proceedings*; (2005); volume 37, Issue 7: 2954-2956.

European Tacrolimus Multicenter Renal Study Group, 1997. European Tacrolimus Multicenter Renal Study Group, 1997. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. *Transplantation* 64: 436–443.

Everly MJ, Everly JJ and Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. *Transplantation*(2008); 86: 1754.

Ferguson RM., Acute-rejection episodes-best predictor of long-term primary cadaveric renal transplant survival *Clin Transplant*8 (1994); 328.

- Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT and Rollin H *et al.* De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years, *Am J Transplant* (2004); 1776: 1785.
- Friend PJ, Rebello P and Oliveira D *et al.* Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. *Transplant Proc* (1995); 27:869.
- Furness PN, Philpott CM and Chorbajian MT *et al.* Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. *Transplantation* (2003); 76: 969.
- Gaber AO, First MR and Tesi RJ *et al.* Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. *Transplantation* (1998); 66: 29.
- Gaston R., Current and evolving immunosuppressive regimens in kidney transplantation. *Am J Kidney Dis.* (2006); 47: 3–21.
- Genberg H., Hansson A. and Wernerson A. *et al.*, Pharmacodynamics of rituximab in kidney allotransplantation. *Am J Transplant* (2006); 6: 2418.
- Gill JS, Tonelli M and Mix CH. The effect of maintenance immunosuppression medication on the change in kidney allograft function. *Kidney Int.* (2004); 65(2): 692-9.
- Gjertson DW. Determinants of long term survival of adult kidney transplants. A 1999 UNOS update. *ClinTranspl* (1999); 341: 352.
- Golshayan D and Pascual M. Minimization of Immunosuppression in Organ TransplantationMinimization of calcineurin inhibitors to improve long-

term outcome in kidney transplantation. *Transplant. Immunology* (2008); 20(1-2): 21-28.

Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P and Stegall M *et al.* Randomized trial of tacrolimus + mycophenolatemofetil or azathioprine versus cyclosporine + mycophenolatemofetil after cadaveric kidney transplantation results at three years. *Transplantation* 75 (2003); 2048: 2053.

Gray D., Shepherd H. and Daar A. *et al.*, Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not? *Lancet* (1978); 1: 117.

Grinyo JM, Gil-Vernet S, Cruzado JM, Caldes A, Riera L and Seron *et al.* Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolatemofetil in cadaveric kidney transplantation: results after 5 years, *Transplant* 16 (2003); 820: 827.

Groth CG, Backman L, Morales JM, Calne R, Kreis H and Lang P *et al.*, Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group, *Transplantation* 67 (1999); 1036: 1042.

Halloran PF and Hunsicker LG. Delayed graft function. *Am J Transplant* (2001); 1: 115: 20.

Hariharan S, Johnson C, Bresnahan B, Taranto S, McIntosh M and Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Engl J Med*(2000); 342: 605–612.

Hariharan S. Long-term kidney transplant survival, *Am J Kidney Dis* 38(suppl 6) (2001); 44.

- Helal L, Abderrahim E, Ben Hamida F, Ounissi M, Essine S, Hedri H, Bardi R, Elgorgi Y, Ben Maiz H, Ben TA and Kheder A. The First Year Renal Function as a Predictor of Long-Term Graft Survival after Kidney Transplantation *Transplantation Proceedings*(2009); 41(2): 648-650.
- Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK. Immunosuppression: practice and trends. *Am J Transplant.* (2003); 3 4:41-52.
- Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. *Transplantation* 1999; 68:1200.
- Fuentes MP and Lechler RI. Chronic graft loss. Immunological and non-immunological factors, *Contrib Nephrol* 146 (2005): 54–64.
- Herrero-Fresneda I, Franquesa M, Torras J, Vidal A, Aran J, Pluvinet R, Lloberas N, Rama I, Cruzado JM, Guliás O and Grinyó JM. Role of Cold Ischemia in Acute Rejection: Characterization of a Humoral-Like Acute Rejection in Experimental Renal Transplantation. *Transplantation Proceedings*, Volume 37, Issue 9, (2005): 3712-3715.
- Horvat LD, Shariff SZ and Garg AX. Global trends in the rates of living kidney donation. *Kidney Int.* (2009); 75(10):1088-98.
- Hricik DE, Zarconi J and Schulak JA. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. *Transplantation* (1989); 47:272.
- Humar A, Payne WD, Sutherland DE And Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. *Transplantation* (2000); 69:235.

Ibrahim HN., Foley R., Tan L., Rogers T., Bailey RF., Guo H., Gross CR. and Matas AJ. Long-term consequences of kidney donation. *N Engl J Med.* (2009)29; 360(5):522-3.

Jensik SC. Tacrolimus in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK506Kidney Transplant Study Group. *Transplant. Proc.*30 (1998): 1216–1218.

Jordan ML, Naraghi R and Shapiro R et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. *Transplantation* (1997); 63:223.

Jordan ML, Shapiro R and Vivas CA, et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. *Transplantation* (1994); 57:860.

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification, *Am J Kidney Dis*39 (suppl 2) (2002); 1.

Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomisedmulticentre study. The Rapamune US Study Group, *Lancet*356 (2000): 194–202.

Kaplan B, Schold JD and Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis, *J Am Soc Nephrol*14 (2003); 2980: 2984.

Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA. And Weir MR. The evaluation of renal transplantation candidates: clinical practice guidelines. *Am J Transplant.*(2001); 1: 23-95.

Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J and Rush D. Long-term deterioration of kidney allograft function. *Am J Transplant.* (2005);5(6):1405-14.

- Kayler LK, Meier-Kriesche HU and Punch JD *et al.*, Gender imbalance in living donor renal transplantation, *Transplantation* 73 (2002); 248.
- Kee TY, Chapman JR and O'Connell PJ *et al.* Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. *Transplantation* (2006); 82:36.
- Keown P. Improving quality of life. The new target for transplantation. *Transplantation* (2001); 72 (Suppl 12): 67–74.
- Kim SJ, Schaubel DE, Jeffery JR and Fenton SS. Centre-specific variation in renal transplant outcomes in Canada. *Nephrol Dial Transplant.* (2004); 19(7):1856-61.
- Knight RJ and Burrows L. The combined impact of donor age and acute rejection on long-term cadaver renal allograft survival , Volume 125, Issue 3, (1999); 318: 324.
- Kouwenhoven E.A., Ijzermans J.N. and Bruin R.W., Etiology and pathophysiology of chronic transplant dysfunction, *TransplInt* 13 (2000); 385.
- Kreis HA and Ponticelli C, Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors, *Transplantation* 71 (2001); 5: 9.
- Kreis JM, Cisterne W, Land L, Wramner JP. Squifflet and Abramowicz D.*et al.*, Sirolimus in association with mycophenolatemofetil induction for the prevention of acute graft rejection in renal allograft recipients, *Transplantation* 69(7) (2000); 1252: 1260.
- Krieger NR, Becker BN and Heisey DM *et al.* Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentically living-related and living-unrelated grafts, *Transplantation* 75 (2003); 1677.

- Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC and Schwab TR *et al.* Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus, *Am J Transplant*6 (2006);514: 522.
- Lennertz A, Fertmann J and Thomae R *et al.* Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases. *Ther Apher Dial* (2003); 7:529.
- Leunissen Kootstra KM and Mooy G *et al.* Plasmapheresis and RATG-induced serum sickness. *Clin Transplant* (1988): 2-5.
- Lindholm, A, Ohlman, S and Albrechtsen, D, *et al.* The impact of acute rejection episodes on long term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. *Transplantation* (1993); 56:307.
- Luke PW, Scantlebury VP and Jordan ML *et al.*, Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin in renal transplant recipients. *Transplantation* (2001); 71:419.
- MacDonald AS and Rapamune Global Study Group, A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts, *Transplantation*71 (2001); 271: 280.
- Madden RL, Mulhern JG And Benedetto BJ.*et al.*, completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. *TransplInt* (2000); 13: 344.
- Magee CC and Pascual M. Update in renal transplantation, *Arch Intern Med*164 (2004); 1373: 1388.

Maluccio M, Sharma V and Lagman M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. *Transplantation* (2003); 76: 597-602.

Marcén R, Fernández-Rodríguez A, Rodríguez-Mendiola N, Ponte B, Galeano C, Villafruela JJ, Teruel JL, Burgos FJ and Ortuño J. Evolution of Rejection Rates and Kidney Graft Survival: *Transplantation Proceedings* Volume 41, Issue 6, (2009); 2357: 2359.

Marcén R, Pacual J and Teruel JL et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine, *Transplantation* 72 (2001); 57.

Margreiter R. and European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group, Efficacy and safety of tacrolimus compared with ciclosporinmicroemulsion in renal transplantation: a randomized multicentre study, *Lancet* 359 (2002); 741: 746.

Marks WH, Wagner D and Pearson TC et al. Organ donation and utilization, 1995-2004: entering the collaborative era. *Am J Transplantation* (2006); 6: 1101-1110.

Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994; 57: 857.

Matas AJ, Lawson W and McHugh L et al. Employment patterns after successful kidney transplantation. *Transplantation* (1996); 61: 729–33.

Matas AJ, Gillingham KJ and Humor A et al. Immunologic and non-immunologic factors: different risks for cadaver and living donor transplantation. *Transplantation* (2000); 69: 54.

Mauiyyedi S And Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment, *Curr Opin Nephrol Hypertens* 11 (2002); 609.

McGee J, Magnus JH, Islam TM, Jaffe BM, Zhang R, Florman SS, Hamm LL, Mruthinti N, Sullivan K and Slakey DP. Donor-Recipient Gender and Size Mismatch Affects Graft Success after Kidney Transplantation, *Journal of the American College of Surgeons* Volume 210, Issue 5, (2010); 718: 725.

Meehan SM, Domer P and Josephson M et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. *Hum Pathol* (2001); 32:205.

Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT and Barr ML *et al.*, Immunosuppression: evolution in practice and trends, 1994–2004, *Am J Transplant* 6 (2006); 1111: 1131.

Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S and Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolatemofetil combined with tacrolimus, *Am J Transplant* 5 (2005); 2273: 228.

Meier-Kriesche HU, Schold JD, Srinivas TR and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era, *Am J Transplant* 4 (2004); 378: 383.

Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN and Morris JA *et al.* Mycophenolatemofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration, *Transplantation* 75 (2003); 1341: 1346.

- Mele TS and Halloran PF. The use of mycophenolatemofetil in transplant recipients, *Immunopharmacology* 47 (2–3) (2000); 215: 245.
- Miller L. Cardiovascular toxicities of immunosuppressive agents. *Transplantation* (2002); 2: 807-902.
- Moll S and Pascual M. Humoral rejection of organ allografts. *Am J Transplant* (2005); 5: 2611.
- Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. *Transplantation* (2004); 78: 181.
- Montgomery RA, Zachary AA and Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. *Transplantation* (2000); 70: 887.
- Montgomery RA, Zachary AA and Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. *JAMA* (2005); 294: 1655–63.
- Mulley WR, Hudson FJ and Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. *Transplantation* (2009); 87: 286.
- Nankivell BJ, Borrows RJ, Fung PJ, CL O'Connell, RD Allen and Chapman JR. The natural history of chronic allograft nephropathy, *N Engl J Med* 349 (2003); 2326: 2333.

Nankivell BJ and Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. *Am J Transplant* (2006); 6.

Nashan B. Is acute rejection the key predictor for long-term outcomes after renal transplant when comparing Calcineurin inhibitors? *Transplantation Reviews* (2009); 23(1): 47-52.

Norman DJ, Barry JM and Bennett WM, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. *Am J Kidney Dis* (1988); 11: 90.

Norman DJ, Shield CF and Henell KR et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. *Transplantation* (1988); 46: 523.

Nyberg G, Blohme I and Norden G. Gender differences in a kidney transplant population, *Nephrol Dial Transplant* 12 (1997); 559.

Ojo AO, Hanson JA and Meier-Kriesche H et al. Survival in recipients of marginal deceased donor kidneys compared with other recipients and wait-listed transplant candidates. *J Am Soc Nephrol* (2001); 12: 589–97.

Ojo AO, Wolfe RA and Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. *Transplantation* (1997); 63: 968–72.

Opelz G . Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet* (2005); 365: 1570–6.

Opelz G and Döhler B. Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. *Transplantation* (2008); 85: 661.

Opelz G, Wujciak T and Ritz E. Association of chronic kidney graft failure with recipient blood pressure, *Kidney Int* 53 (1998); 217: 222.

Park K, Lee JH and Huh KH, et al. Exchange living-donor kidney transplantation: diminution of donor organ shortage. *Transplant Proc* (2004); 36: 2949–51.

Pascual M, Saidman S and Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. *Transplantation* (1998); 66: 1460.

Pascual M, Theruvath T., Kawai T., Tolkoff N.-Rubin and Cosimi, A.B. Strategies to improve long-term outcomes after renal transplantation, *N Engl J Med* 346 (2002); 580: 590.

Paul LC, Soito K, Davidoff A and Benediktsson H: Growth factor transcripts in rat renal transplants. *Am. J. Kidney Dis.* (1996); 28(3): 441-450.

Peleg AY, Husain S and Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. *Clin Infect Dis* (2007); 44: 204.

Pham PT, Pham PM, Miller JM and Pham PC. Polyclonal antibody-induced serum sickness presenting as rapidly progressive descending paralysis. *Transplantation* (2007); 83:1657.

Pichette V, Bonnardeaux, A and Prudhomme, L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. *Am J Kid Dis* (1996); 28: 105.

Pirsch JD, Miller J, Deierhoi MH, Vincenti F and Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after

cadaveric renal transplantation FK506 Kidney Transplant Study Group, Transplantation 63 (1997); 977: 983.

Poduval RD, Kadambi PV, Josephson MA, et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation (2005); 79: 228.

Poggio ED, Clemente M and Riley J *et al.*, Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy, J Am Soc Nephrol 15 (2004); 1952.

Ponticelli C, Minetti L, Di Palo FQ, Vegeto A, Belli L, Corbetta G, Tarantino A, Civati G. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation (1988); 45(5): 908-13.

Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. Kidney Int. (2002); 62(5): 1848-54.

Port FK, Merino RM, Goodrich NP, Wolfe RA. Recent trends and results for organ donation and transplantation in the United States, 2005. Is J Transplant (2006); 6: 1095–100.

Prommool S, Jhangri GS, Cockfield SM and Halloran PF. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol. (2000); 11(3): 565-73.

Quiroga I, McShane P, Koo DD, Gray D, Friend PJ, Fuggle S and Darby C. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant. (2006); 21(6): 1689-96.

Racusen LC, Colvin RB and Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. *Am J Transplant* (2003); 3: 708.

Racusen LC, Solez K and Colvin RB: The Banff 97 working classification of renal pathology. *Kidney Int* 1999; 55(2): 713-723.

Raftery AT and Delbridge MS. *Renal transplantation Surgery (Oxford)* (2005); 23(4): 148-152.

Rescue therapy with mycophenolatemofetil. The MycophenolateMofetil Renal Refractory Rejection Study Group. *Clin Transplant* (1996); 10: 131.

Roberts IS, Reddy S and Russell C et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. *Transplantation* (2004); 77: 1194.

Rocha PN, Butterly DW and Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. *Transplantation* (2003); 75: 1490.

Rush DN, Henry SF and Jeffery JR et al. Histological findings in early routine biopsies of stable renal allograft recipients. *Transplantation* (1994); 57: 208.

Sabek O, Dorak MT and Kotb M: Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathological evaluation. *Transplantation* (2002); 74(5): 701-707.

Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G and Bertoni E.

Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. *Transplantation*. (2006); 81(2): 202-6.

Schaub S, Rush D and Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. *J Am Soc Nephrol* (2004); 15: 219.

Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. *Am J Kidney Dis* (1994); 23: 138.

Segev DL, Simpkins RA and Hartman EC et al. ABO incompatible high-titer transplantation without splenectomy or anti-CD20 treatment. *Am J Transplant* (2005); 5: 2750–5.

Shapiro R, Jordan ML and Scantlebury VP, et al. Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? *Transplantation* (2000); 69: 440.

Shimmura H, Tanabe K and Ishida H, et al. Lack of correlation between results of ABO-incompatible living kidney transplants and anti-ABO blood type titers under current immunosuppression. *Transplantation* (2005); 80: 985–8.

Shinn C, Malhotra D and Chan L, et al. Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. *Am J Kidney Dis* (1999); 34: 304.

Shirakawa H, Ishida H and Shimizu T et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. *Clin Transplant* (2010).

Sijpkens YWJ, Joosten SA, Paul LC. Chronic rejection in renal transplantation
Original Research Article Transplantation Reviews, Volume 17, Issue 3,
July (2003); 117: 130.

Solez K, Axelsen RA and Benediktsson H, et al. International standardization of
criteria for the histologic diagnosis of renal allograft rejection: the Banff
working classification of kidney transplant pathology. *Kidney Int* (1993);
44: 411.

Solez K, Colvin RB and Racusen LC, et al. Banff '05 Meeting Report: differential
diagnosis of chronic allograft injury and elimination of chronic allograft
nephropathy ('CAN'). *Am J Transplant* (2007); 7: 518.

Solez K, Colvin RB and Racusen LC, et al. Banff 07 classification of renal
allograft pathology: updates and future directions. *Am J Transplant*
(2008); 8: 753.

Solez K, Vincenti F and Filo R.S., Histopathologic findings from 2-year protocol
biopsies from a U.S. multicenter kidney transplant trial comparing
tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant
Study Group, *Transplantation* 66 (12) (1998); 1736: 1740.

Sorof JM, Vartanian RK and Olson JL, et al. Histopathological concordance of
paired renal allograft biopsy cores. Effect on the diagnosis and
management of acute rejection. *Transplantation* (1995); 60: 1215.

Spital A. Living kidney donors: still a valuable resource. *Curr Opin Organ
Transplant* (1998); 3: 205–11.

Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC and Chamberlain
et al., Kidney transplantation with rabbit antithymocyte globulin
induction and sirolimus monotherapy, *Lancet* 360 (9346) (2002); 1662:
1664.

- Takahashi K, Takahara S and Uchida K et al. Successful results after 5 years of tacrolimus therapy in ABO-incompatible kidney transplantation in Japan. *Transplant Proc* (2005); 37: 1800–3.
- Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J and Wu C *et al.*, Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy, *Am J Transplant* 6 (10) (2006); 2409: 2417.
- Tan HP, Smaldone MC and Shapiro R. Immunosuppressive preconditioning or induction regimens. Evidence to date, *Drugs* 66 (12) (2006); 1535: 1545.
- Taylor GS, Prather JS, Norman DJ, Mattos AM, Mogilishetty G, Conlin MJ and Barry JM, living unrelated donor renal transplantation: a single center experience *The Journal of Urology* Volume 174, Issue 1, (2005); 223: 225.
- Terasaki PI and Cai J. Humoral theory of transplantation: further evidence, *Curr Opin Immunol* 17 (2005); 541.
- Terasaki PI and Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. *Transplantation* (2005); 80(9): 1194-7.
- Thaunat O, Legendre C and Morelon E, et al. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? *Transplantation* (2007); 84: 671.
- Thomas PG, Ishihara K, Vaidya S and Gugliuzza KK. Campath and renal transplant rejection. *Clin Transplant* (2004); 18: 759.
- Toki D, Ishida H and Horita S et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. *Transpl Int* (2009); 22: 447.

- Tullius SG, Reutzel-Selke A, Bachmann U, Jurisch A, Nieminen-Kelhä M, Pratschke J, Jonas S, Steinmüller T, Volk HD and Neuhaus P. Influence of recipient and donor age on long-term renal allograft function in an experimental model. *Transplant Proc.* (2001); 33(7-8): 3345-6.
- Tyden G, Kumlien G and Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. *Transplantation* (2003); 76: 730 –1.
- Tyson, Castle EP, Ko EY, Andrews PE, Heilman RL, KL Mekeel, Moss A A, Mulligan DC and Reddy KS. Living Donor Kidney Transplantation With Multiple Renal Arteries in the Laparoscopic Era *Urology*, Volume 77, Issue 5, (2011); 1116:1121.
- US Renal Data System: Annual Data Report: Atlas of End-Stage Renal. Disease in the United States, Bethesda, National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (2006).
- Vereerstraeten P, Abramowicz D, de Pauw L and Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. *Transplantation* (1997); 63:1739.
- Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, JM Campistol *et al.* and DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring versus Tacrolimus) Investigators, Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus, *Am J Transplant* 7 (6) (2007); 1506: 1514.
- Vincenti F, Jensik SC, Filo RS, Miller J. and Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years, *Transplantation* 73 (2002); 775: 782.

Vineyard GC, Fadem SZ and Dmochowski J et al. Evaluation of corticosteroid therapy for acute renal allograft rejection. *SurgGynecolObstet*(1974); 138:225.

Whiting JF, Golconda M and Smith R, et al. Economic cost of expanded criteria donors in renal transplantation. *Transplantation* (1998); 65: 204–7.

Wigmore SJ and Forsythe JL. To biopsy or not to biopsy. *Transplantation* (2003); 76:909.

Wiland AM, Fink JC and Weir: Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. *Transplantation* (2004); 77(3): 422-425.

Wong Venetz JP, Tolkoff-Rubin N and Pascual M. immunosuppressive strategies in kidney transplantation: which role for calcineurin inhibitors? *Transplantation* 80 (3) (2005); 289: 296.

Woodle ES, Thistlethwaite JR and Gordon JH et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. *Transplantation* (1996); 62:594.

www.USRDS.org (Accessed on May 16, 2009).

www.ustransplant.org/annual_reports/2008, accessed 2/10.

Yoo SW, Kwon OJ and Kang CM. Preemptive living-donor renal transplantation: outcome and clinical advantages. *Transplantation Proceedings* 2009; 41(1):117-120.

Yuksel SE, El-Baz A, Farag AA, Abo El-Ghar ME, Eldiasty TA and Ghoneim MA. International Congress Series Automatic detection of renal rejection after kidney transplantation (2005); volume 1281: 773-778.

Zand MS, Vo T and Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation (2005); 79:1507.

Zhang PL, Malek SK and Prichard JW, et al. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy. Am J Transplant (2005); 5: 604.

Zhang Q, Liang LW and Gjertson DW *et al.* Development of posttransplant anti-donor HLA antibodies is associated with acute humoral rejection and early graft dysfunction, Transplantation 79 (2005); 591.

Zimmerman D, Donnelly S and Miller J *et al.* Gender disparity in living renal transplantation donation, Am J Kidney Dis 36 (2000); 534.